Xiuli Sun

发表

Comparison of CART 19 and autologous stem cell transplantation for refractory / relapsed non-Hodgkin ’ s lymphoma

Depei Wu, Ting Xu, Jin Zhou, 2019 .

Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.

Depei Wu, Ting Xu, Jin Zhou, 2019, JCI insight.

Comparison of CAR-T19 and autologous stem cell transplantation for refractory/ relapsed non-Hodgkin’s lymphoma

Depei Wu, Ting Xu, Jin Zhou, 2019 .

Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.

Xiaodong Ma, Zhihao Liu, Changyuan Wang, 2019, European journal of medicinal chemistry.

Case Report: Multimodal Imaging Guides the Management of an Eosinophilic Leukemia Patient With Eosinophilic Myocarditis and Intracardiac Thrombus

Y. Liu, Xiuli Sun, Xinxin Zhang, 2022, Frontiers in Cardiovascular Medicine.

Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.

Huijun Sun, Xiaodong Ma, Zhihao Liu, 2018, Bioorganic & medicinal chemistry.

JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.

Xiaodong Ma, Changyuan Wang, Kexin Liu, 2019, Bioorganic chemistry.

Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.

Huijun Sun, Xiaodong Ma, Bin Wu, 2020, Bioorganic chemistry.

Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.

Xiaodong Ma, Zhihao Liu, Q. Meng, 2018, European journal of medicinal chemistry.

Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Bo Sun, Huijun Sun, Xiaodong Ma, 2019, ChemMedChem.

Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.

Xiaodong Ma, Changyuan Wang, Kexin Liu, 2017, European journal of medicinal chemistry.

Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer.

Xiaodong Ma, Changyuan Wang, Guoping Huang, 2019, Bioorganic chemistry.

Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement

Depei Wu, Jin Zhou, Ying Zhang, 2021, Frontiers in Immunology.

Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.

Xiaodong Ma, Changyuan Wang, Kexin Liu, 2019, Bioorganic chemistry.

Validation of the imatinib-therapy failure model

Fei Li, R. Gale, Jianda Hu, 2023, Leukemia.

Histiocytoid giant cellulitis-like Sweet syndrome at the site of sternal aspiration: A case report and review of literature

Xiuli Sun, Jing Ni, D. Zhao, 2021, World journal of clinical cases.

Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer.

Xiaodong Ma, Changyuan Wang, Xu Zheng, 2022, European journal of medicinal chemistry.

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

Jingjing Zhang, Yan Yan, Jinsong Yan, 2023, Frontiers in oncology.

Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.

Huijun Sun, Xiaodong Ma, Changyuan Wang, 2019, Bioorganic & medicinal chemistry.